Indivior Pharmaceuticals Inc. Common Stock vs Vaxcyte Inc. Common Stock — how do they compare? Indivior Pharmaceuticals Inc. Common Stock trades at $34.3 (market cap $4.18B), while Vaxcyte Inc. Common Stock trades at $67.27 (market cap $10.51B). The key difference: Vaxcyte Inc. Common Stock is far larger — about 2.5× Indivior Pharmaceuticals Inc. Common Stock's market cap, and Vaxcyte Inc. Common Stock is trading nearer its 52-week high, Indivior Pharmaceuticals Inc. Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Indivior Pharmaceuticals Inc. Common Stock for 0 Days and Vaxcyte Inc. Common Stock for 0 Days on average.
| INDV | PCVX | |
|---|---|---|
Market Cap | $4.18B | $10.51B |
Volume | 1,819,746 | 2,644,694 |
Sector | Health | Health |
52-Week High | $41.83 | $73.82 |
52-Week Low | $24.09 | $40.32 |
Typical Hold Time | 0 Days | 0 Days |
Enterprise Value | $4.47B | $9.14B |
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Indivior Pharmaceuticals, Inc. is a pharmaceutical company focused on treatments for opioid use disorder and other addiction-related conditions, including its Suboxone film and tablet products.
Read more on INDV →Vaxcyte, Inc. is a clinical-stage vaccine company that engineers protein-based vaccines to prevent bacterial diseases such as invasive pneumococcal disease, using its proprietary cell-free protein synthesis platform to develop candidates including the pneumococcal conjugate vaccines VAX-31 and VAX-24.
Read more on PCVX →